U.S. President Donald Trump (center) speaks during an event on improving health care affordability in the Oval Office of the White House April 23, 2026 in Washington, DC.
Alex Wong | Getty Images
Regeneron has agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White House announced Thursday.
The biotech company will also offer the first gene therapy for hearing loss to eligible U.S. patients free of charge, following regulatory approval of the product earlier Thursday.
Regeneron is the latest in a series of major drugmakers to make price concessions on new and existing drugs in deals with Trump. The deals are part of its “most favored nation” effort to tie U.S. drug prices to the lowest prices in other developed countries.
The agreements also exempt companies from tariffs for three years, including Trump’s planned levies of up to 100% on certain pharmaceutical products. The Trump administration has signed 17 deals so far, but is negotiating more with other biotech and pharmaceutical companies, CMS Deputy Administrator Chris Klomp said at a White House event Thursday.
Regeneron’s deal comes just hours after the Food and Drug Administration approved the company’s gene therapy, Otarmeni, which restored hearing in a small number of deaf children. The treatment received accelerated approval under the FDA’s National Priority Voucher program.
The drug targets an ultra-rare genetic disease caused by a mutation that prevents the body from making a protein needed for hearing. This is a major breakthrough for a subset of patients who have long relied on cochlear implants.
In a March note, Piper Sandler analysts estimated the gene therapy would bring in peak sales of $130 million.
— CNBC’s Angelica Peebles contributed to this report.